慢传输型便秘的药物治疗新进展  

Current pharmacologic therapies for chronic slow transit constipation

作　　者：方秀才[1] 

机构地区：[1]中国医学科学院北京协和医学院、北京协和医院消化内科,北京100730

出　　处：《第三军医大学学报》2013年第21期2259-2261,共3页Journal of Third Military Medical University

基　　金：“十一五”国家科技支撑计划(2007BAI04B01);国家高技术研究发展计划(863计划,2010AA023007)~~

摘　　要：慢性便秘是一种常见病症,其中大部分患者属于功能性便秘,其症状的产生与结肠传输延缓或伴有肛门直肠功能异常有关。结肠传输延缓导致粪便在肠道停留时间过长、水分过度吸收,出现排便次数减少（每周少于3次）、粪便干硬、缺乏便意、排便费力等症状。以排便次数减少、粪便干硬为主要表现的功能性便秘患者,高度提示其属于慢传输型便秘。结合胃肠传输时间测定（gastrointestinal transit time,GITT）、肛门直肠测压等可明确结肠传输延缓的程度和主要肠段。Functional constipation, manifesting as infrequent bowel movements, hard or lumpy stools, is a disorder of colonic motility and slow transit function, as well as poor intestinal fluid secretion or over absorption. Short- and long-term clinical trials had been carried out to evaluate the efficacy and safety of a selective 5-HT4 receptor agonist prnealopride, a chloride channel-2 activator lubiprostone, and a synthetic guanylate cyclase C agonist linaclotide on chronic constipation patients with infrequent bowel movements. These novel pharmacologic agents offered alternative options for the therapy of slow transit constipation when the patients got no satisfactory relief for their constipation symptoms from conventional laxatives.

关 键 词：功能性便秘 慢传输型便秘 药物治疗 

分 类 号：R574.62[医药卫生—消化系统] R975.3[医药卫生—内科学]